Synthesis of cyclopropyl indoles and cyclohepta[B]indoles, pharmaceutical compositions containing them and method of using them

US10174008B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10174008-B2
Application numberUS-201515545858-A
CountryUS
Kind codeB2
Filing dateDec 3, 2015
Priority dateDec 3, 2014
Publication dateJan 8, 2019
Grant dateJan 8, 2019

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Methods of making indole analogs using a rhodium-containing catalyst are described, along with methods of using the compounds to treat hyperglycemic, hyperlipidemic, or autoimmune disorders in mammals, and corresponding pharmaceutical compositions. Disclosed herein is a method of making indoles. The method comprises contacting a reactant of formula I wherein E is a protecting group, —SO2-Aryl, or —SO2-substituted-Aryl; and R and R2 are independently selected from the group consisting of hydrogen, halo, C1-C12-alkyl and aryl; with a rhodium(1)-containing catalyst.

First claim

Opening claim text (preview).

What is claimed is: 1. A method of making indoles, the method comprising: contacting a reactant of formula I: wherein E is a protecting group, —SO 2 -Aryl, or —SO 2 -substituted-Aryl; and R 1 and R 2 are independently selected from the group consisting of hydrogen, halo, C 1 -C 12 -alkyl, and aryl; with a rhodium(I)-containing catalyst, in the presence or absence of an alkene-containing co-reactant, for a time and at a temperature to yield a product mixture comprising a compound selected from the group consisting of formula (II), (III), and (IV): wherein R 1 , R 2 , and E are as defined previously, and R 3 is hydrogen in the absence of the alkene-containing co-reactant, and R 3 is a substituent corresponding to the alkene-containing co-reactant in the presence of the alkene-containing co-reactant. 2. The method of claim 1 , which yields a product mixture comprising a compound of formula (II). 3. The method of claim 1 , which yields a product mixture comprising a compound of formula (III). 4. The method of claim 1 , which yields a product mixture comprising a compound of formula (IV). 5. The method of claim 1 , conducted in the absence of the alpha-alkene-containing co-reactant. 6. The method of claim 1 , wherein the alkene-containing co-reactant is present and is selected from the group consisting of: wherein R 4 , R 5 , and R 6 are each independently selected from the group consisting of hydrogen, C 1 -C 12 -alkyl, C 1 -C 12 -alkyloxy, C 1 -C 12 -haloalkyl, and C 1 -C 12 -hydroxyalkyl; and E is a protecting group. 7. The method of claim 1 , wherein the rhodium(I)-containing catalyst comprises [Rh(CO) 2 Cl] 2 . 8. The method of claim 7 , which yields a product mixture comprising a compound of formula (II). 9. The method of claim 7 , which yields a product mixture comprising a compound of formula (III). 10. The method of claim 7 , which yields a product mixture comprising a compound of formula (IV). 11. The method of claim 7 , conducted in the absence of the alpha-alkene-containing co-reactant. 12. The method of claim 7 , wherein the alkene-containing co-reactant is present and is selected from the group consisting of: wherein R 4 , R 5 , and R 6 are each independently selected from the group consisting of hydrogen, C 1 -C 12 -alkyl, C 1 -C 12 -alkyloxy, C 1 -C 12 -haloalkyl, and C 1 -C 12 -hydroxyalkyl; and E is a protecting group. 13. The method of claim 1 , wherein the reactant of formula I is contacted with the catalyst in the presence of carbon monoxide. 14. The method of claim 13 , which yields a product mixture comprising a compound of formula (II). 15. The method of claim 13 , which yields a product mixture comprising a compound of formula (III). 16. The method of claim 13 , which yields a product mixture comprising a compound of formula (IV). 17. The method of claim 13 , conducted in the absence of the alpha-alkene-containing co-reactant. 18. The method of claim 13 , wherein the alkene-containing co-reactant is present and is selected from the group consisting of: wherein R 4 , R 5 , and R 6 are each independently selected from the group consisting of hydrogen, C 1 -C 12 -alkyl, C 1 -C 12 -alkyloxy, C 1 -C 12 -haloalkyl, and C 1 -C 12 -hydroxyalkyl; and E is a protecting group. 19. A method of treating hyperglycemic, hyperlipidemic, or autoimmune disorders in mammals, wherein the autoimmune disorders are selected from the group consisting of arthritis, multiple sclerosis, psoriasis, and inflammatory bowel disease, the method comprising administering to a mammal an anti-hyperglycemic-effective, anti-hyperlipidemic-effective, or anti-autoimmune-effective amount of one or more compounds selected from the group consisting of: wherein R 1 and R 2 are independently selected from the group consisting of hydrogen, halo, C 1 -C 12 -alkyl, and aryl; and R 3 is selected from the group consisting of: wherein R 4 , R 5 , and R 6 are each independently selected from the group consisting of hydrogen, C 1 -C 12 -alkyl, C 1 -C 12 -alkyloxy, C 1 -C 12 -haloalkyl, and C 1 -C 12 -hydroxyalkyl; E is a protecting group or a hydrogen atom; or a pharmaceutically suitable salt thereof. 20. A pharmaceutical composition for treating hyperglycemic, hyperlipidemic, or autoimmune disorders in mammals, wherein the autoimmune disorders are selected from the group consisting of arthritis, multiple sclerosis, psoriasis, and inflammatory bowel disease, the composition comprising an anti-hyperglycemic-effective, anti-hyperlipidemic-effective, or anti-autoimmune-effective amount of one or more of the compounds selected from the group consisting of: wherein R 1 and R 2 are independently selected from the group consisting of hydrogen, halo, C 1 -C 12 -alkyl, and aryl; and R 3 is selected from the group consisting of: wherein R 4 , R 5 , and R 6 are each independently selected from the group consisting of hydrogen, C 1 -C 12 -alkyl, C 1 -C 12 -alkyloxy, C 1 -C 12 -haloalkyl, and C 1 -C 12 -hydroxyalkyl; E is a protecting group or a hydrogen atom; or a pharmaceutically suitable salt thereof; in combination with a pharmaceutically suitable carrier.

Assignees

Inventors

Classifications

  • Introduction of protecting groups or activating groups, not provided for in the preceding groups · CPC title

  • Cyclisation · CPC title

  • containing rhodium · CPC title

  • Carbenes or carbynes, i.e.(image) · CPC title

  • Cyclopropanations · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10174008B2 cover?
Methods of making indole analogs using a rhodium-containing catalyst are described, along with methods of using the compounds to treat hyperglycemic, hyperlipidemic, or autoimmune disorders in mammals, and corresponding pharmaceutical compositions. Disclosed herein is a method of making indoles. The method comprises contacting a reactant of formula I wherein E is a protecting group, —SO2-Aryl, …
Who is the assignee on this patent?
Wisconsin Alumni Res Found
What technology area does this patent fall under?
Primary CPC classification C07D405/08. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Jan 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).